Acuta Capital Partners’s SpringWorks Therapeutics SWTX Stock Holding History

Acuta Capital Partners’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,000	Closed	-$365K	–	41
2023 Q4	$365K	Buy	+10,000	New	+$261K	0.21%	35
2022 Q4	–	Sell	-5,000	Closed	-$143K	–	46
2022 Q3	$143K	Hold	5,000	–	–	0.06%	40
2022 Q2	$123K	Buy	+5,000	New	+$183K	0.07%	40

Other funds holding SWTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Acuta Capital Partners's SWTX Position: Q1 2024 in Review

Acuta Capital Partners sold out of SpringWorks Therapeutics (SWTX) in Q1 2024, closing a stake of 10,000 shares — an estimated $365K sold.

Acuta Capital Partners first reported a position in SWTX in Q2 2022 and held it in 3 quarters. The position peaked at $365K in Q4 2023. 217 funds tracked by Wall St. Rank hold SWTX as of Q1 2024.

Acuta Capital Partners reported no remaining SpringWorks Therapeutics position as of Q1 2024 after selling out during the quarter.
Acuta Capital Partners sold 10,000 SpringWorks Therapeutics shares in Q1 2024, an estimated $365K.
Acuta Capital Partners first reported a position in SpringWorks Therapeutics in Q2 2022 and held it in 3 quarters.
Acuta Capital Partners's SpringWorks Therapeutics position peaked at $365K in Q4 2023.
217 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q1 2024.

Based on Acuta Capital Partners's 13F filing for Q1 2024, filed 15 May 2024.